AbbVie Inc. / Safeway Inc. / Rubenstein Communications Inc. / Berry Consultants / /
Continent
North America / /
Currency
USD / / /
Event
FDA Phase / /
Facility
National Cancer Institute / UCSF Helen Diller Family Comprehensive Cancer Center / The University of Texas MD Anderson Cancer Center / University of California / /
IndustryTerm
pharmaceutical industry / systems technology / pharmaceutical and other / food / /
MedicalCondition
cancers / entire cancer / tumor / cancer / disease / fast-acting cancers / individual patients’ tumors / early breast cancer / HER2positive/HR-negative disease / triple-negative breast cancer / different cancer / breast cancer / /
MedicalTreatment
experimental therapies / chemotherapy / surgery / /
Organization
National Cancer Institute / Department of Biostatistics / Foundation for the National Institutes of Health / QuantumLeap’s mission / Foundation for the NIH Announces First Results / UCSF Helen Diller Family Comprehensive Cancer Center / FDA / University of California at San Francisco / Foundation for the National Institutes of Health Bethesda / Carol Frank Buck Breast Care Center / University of Texas / /
Person
Donald A. Berry / Laura J. Esserman / Maria Freire / Triple-Negative Breast Cancer Bethesda / Alison Hendrie / Alexandra Sturm / / /
Position
professor of surgery / I-SPY 2 team / professor / I-SPY / model for research / director / Breast Cancer Clinical Trial I-SPY / founder / President and Executive Director / /
FROM: The Foundation for the National Institutes of Health Bethesda, Maryland CONTACT: